Journal of geriatric oncology最新文献

英文中文

Geriatric assessment in older patients with pancreatic cancer: Adding another piece to the puzzle 老年胰腺癌患者的老年评估：增加另一块拼图

IF 2.7 3区医学 Q3 GERIATRICS & GERONTOLOGY

Journal of geriatric oncology

Pub Date : 2026-03-01 Epub Date: 2026-01-29 DOI: 10.1016/j.jgo.2026.102891

Giulia Giordano , Luca Mastrantoni , Giuseppe Ferdinando Colloca , Francesco Landi

引用次数: 0

Reflections on treatment decision making in older adults with cancer 对老年癌症患者治疗决策的思考。

IF 2.7 3区医学 Q3 GERIATRICS & GERONTOLOGY

Journal of geriatric oncology

Pub Date : 2026-03-01 Epub Date: 2025-12-08 DOI: 10.1016/j.jgo.2025.102830

Vincent E.S. Allott , Michael B. Fertleman , Louis J. Koizia , Benjamin H.L. Harris

引用次数: 0

Review of current best practice in radiation oncology for older adults with cancer: Updates from the International Society of Geriatric Oncology (SIOG) Task Force 国际老年肿瘤学会（SIOG）工作组的最新进展：对目前老年癌症患者放射肿瘤学最佳实践的回顾。

IF 2.7 3区医学 Q3 GERIATRICS & GERONTOLOGY

Journal of geriatric oncology

Pub Date : 2026-03-01 Epub Date: 2025-12-21 DOI: 10.1016/j.jgo.2025.102839

Lucinda Morris , Niluja Thiruthaneeswaran , Anita O'Donovan , Noam VanderWalde , Anthea Cree , Surbhi Grover , Stefan Starup Jeppesen , Richard Simcock

Radiotherapy (RT) is a vital and effective cancer treatment that contributes to over 40 % of cancer cures. RT is also fundamental to palliation and improving quality of life in almost all advanced malignancies. The specialty of radiation oncology has undergone dramatic technological advances over the past decade with increasing sophistication of treatment planning and delivery leading to improved cure rates and reduced side effects. For older adults with cancer, RT represents an excellent treatment option due to its effectiveness, limited systemic toxicity, convenience, and tolerability. Advanced techniques such as stereotactic body radiotherapy (SBRT) and hypofractionated regimens are highly effective non-invasive treatment options that may avoid the need for hospital admission, the potential mortality and morbidity of surgery and/or the toxicities of systemic therapy. Historically, the role of RT for older adults has not been comprehensively assessed or defined due to the limited recruitment of older adults to clinical trials. Fortunately, the increasing number of RT trials tailored to specifically explore outcomes for older people is expanding the body of evidence for this priority research area.

This updated expert position paper from the SIOG (International Society of Geriatric Oncology) Task Force seeks to provide an overview of the current role of RT in the management of older adults with cancer. The position paper is informed by the geriatric radiation oncology clinical expertise of the SIOG Task Force and emerging evidence in the field since the publication of the original 2014 position paper. Topics covered include the fundamentals of geriatric oncology as applied to radiation oncology, options for dose fractionation schedules and techniques across pre-defined tumor sites and appropriate individualised modifications of regimens in the setting of frailty, discussion of expected tolerability and toxicity (if any) in older adults, and the unique perspectives of care around older adults requiring RT in low- and middle-income countries.

放射治疗（RT）是一种重要而有效的癌症治疗方法，占癌症治愈率的40%以上。在几乎所有晚期恶性肿瘤中，放疗也是缓解和改善生活质量的基础。放射肿瘤学专业在过去十年中经历了巨大的技术进步，治疗计划和交付越来越复杂，从而提高了治愈率，减少了副作用。对于患有癌症的老年人，放疗是一种很好的治疗选择，因为它的有效性、有限的全身毒性、便捷性和耐受性。立体定向全身放射治疗（SBRT）和低分割治疗方案等先进技术是非常有效的非侵入性治疗选择，可以避免住院，避免手术的潜在死亡率和发病率和/或全身治疗的毒性。从历史上看，由于临床试验中老年人的招募有限，RT对老年人的作用尚未得到全面评估或定义。幸运的是，越来越多专门针对老年人探索结果的RT试验正在扩大这一优先研究领域的证据体系。这是SIOG（国际老年肿瘤学会）工作组更新的专家立场文件，旨在概述目前放疗在老年癌症患者管理中的作用。该立场文件是由SIOG工作组的老年放射肿瘤学临床专业知识和自2014年原始立场文件发布以来该领域的新证据提供的。所涵盖的主题包括应用于放射肿瘤学的老年肿瘤学基础知识，在预先定义的肿瘤部位选择剂量分割时间表和技术，以及在虚弱的情况下对方案进行适当的个性化修改，讨论老年人的预期耐受性和毒性（如果有的话），以及低收入和中等收入国家中需要放射治疗的老年人护理的独特观点。

{"title":"Review of current best practice in radiation oncology for older adults with cancer: Updates from the International Society of Geriatric Oncology (SIOG) Task Force","authors":"Lucinda Morris , Niluja Thiruthaneeswaran , Anita O'Donovan , Noam VanderWalde , Anthea Cree , Surbhi Grover , Stefan Starup Jeppesen , Richard Simcock","doi":"10.1016/j.jgo.2025.102839","DOIUrl":"10.1016/j.jgo.2025.102839","url":null,"abstract":"<div><div>Radiotherapy (RT) is a vital and effective cancer treatment that contributes to over 40 % of cancer cures. RT is also fundamental to palliation and improving quality of life in almost all advanced malignancies. The specialty of radiation oncology has undergone dramatic technological advances over the past decade with increasing sophistication of treatment planning and delivery leading to improved cure rates and reduced side effects. For older adults with cancer, RT represents an excellent treatment option due to its effectiveness, limited systemic toxicity, convenience, and tolerability. Advanced techniques such as stereotactic body radiotherapy (SBRT) and hypofractionated regimens are highly effective non-invasive treatment options that may avoid the need for hospital admission, the potential mortality and morbidity of surgery and/or the toxicities of systemic therapy. Historically, the role of RT for older adults has not been comprehensively assessed or defined due to the limited recruitment of older adults to clinical trials. Fortunately, the increasing number of RT trials tailored to specifically explore outcomes for older people is expanding the body of evidence for this priority research area.</div><div>This updated expert position paper from the SIOG (International Society of Geriatric Oncology) Task Force seeks to provide an overview of the current role of RT in the management of older adults with cancer. The position paper is informed by the geriatric radiation oncology clinical expertise of the SIOG Task Force and emerging evidence in the field since the publication of the original 2014 position paper. Topics covered include the fundamentals of geriatric oncology as applied to radiation oncology, options for dose fractionation schedules and techniques across pre-defined tumor sites and appropriate individualised modifications of regimens in the setting of frailty, discussion of expected tolerability and toxicity (if any) in older adults, and the unique perspectives of care around older adults requiring RT in low- and middle-income countries.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102839"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145809518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pre- and post-radiation therapy quality of life in geriatric cancer patients 放射治疗前后老年癌症患者的生活质量

IF 2.7 3区医学 Q3 GERIATRICS & GERONTOLOGY

Journal of geriatric oncology

Pub Date : 2026-03-01 Epub Date: 2026-03-13 DOI: 10.1016/j.jgo.2026.102885

R. Agrawal , J. Banerjee , M. Bhowmik , N. Aggarwal

引用次数: 0

Impact of dose reductions on adjuvant abemaciclib efficacy in older adults with breast cancer 剂量减少对老年乳腺癌患者阿贝马昔利辅助治疗效果的影响

IF 2.7 3区医学 Q3 GERIATRICS & GERONTOLOGY

Journal of geriatric oncology

Pub Date : 2026-03-01 Epub Date: 2026-03-13 DOI: 10.1016/j.jgo.2026.102874

V. Slavova-Boneva , J. Crimmin , B. Thwaites , C. Chan , W. Sun , B. Gurung , S. Farag , N. Battisti

引用次数: 0

Long-term survival prediction in older women with stage I-II breast cancer using decision tree-based machine learning 使用基于决策树的机器学习预测老年1 - 2期乳腺癌妇女的长期生存。

IF 2.7 3区医学 Q3 GERIATRICS & GERONTOLOGY

Journal of geriatric oncology

Pub Date : 2026-03-01 Epub Date: 2025-12-16 DOI: 10.1016/j.jgo.2025.102828

Hyuna Yoon , Yeijin Kim , Sola Han , Hae Sun Suh , Chanhyun Park

Introduction

Predicting survival in older women with early breast cancer can guide personalized care and improve outcomes. Aging is an individualized process that influences tumor characteristics and survival, with cardiovascular disease (CVD) being the leading non-cancer cause of death due to cardiovascular risk factors. This study aimed to develop and validate machine learning (ML) models to predict all-cause, breast cancer-related, and CVD-related mortality in older women with stage I-II, hormone receptor-positive breast cancer at the U.S. population level. To address the heterogeneity associated with aging, we created separate models for two age groups (66–79 and ≥ 80 years).

Materials and methods

Using the 2006–2019 SEER–Medicare database, we identified women aged ≥66 years diagnosed with stage I–II breast cancer, representing early-stage invasive disease, who initiated adjuvant endocrine therapy (AET) between 2007 and 2009. The first date of AET use was defined as the index date. We assessed pre-existing comorbidities during the one year prior to the index date and followed patients for up to 10 years or until death. Outcomes included all-cause mortality, breast cancer-related mortality, and CVD-related mortality. We developed survival prediction models using the decision tree-based algorithms for the two age groups. Model performance was evaluated using the mean area under the receiver operating characteristic curve (AUROC), and model interpretability was enhanced using Shapley Additive Explanations.

Results

Among 10,104 women, all six models achieved a mean AUROC >0.7 using the random survival forest algorithm (RSF), indicating strong predictive performance. For all-cause mortality, key predictors in both age groups included age, screenings for suspected conditions (abnormal findings without diagnosis), and congestive heart failure. Tumor size, cancer stage, and secondary malignancies were most predictive of breast cancer-related mortality, while congestive heart failure, heart valve disorders, and other ill-defined heart diseases were critical for CVD-related mortality.

Discussion

We developed ML-based survival models across outcomes and age group using the decision tree-based algorithms to predict mortality in older women with stage I-II breast cancer. RSF demonstrated the best performance, with age, screenings for suspected conditions, and congestive heart failure consistently emerging as key predictors. Targeting these factors may enhance cardio-oncology care.

预测老年早期乳腺癌患者的生存率可以指导个性化护理并改善预后。衰老是一个影响肿瘤特征和生存的个体化过程，心血管疾病（CVD）是心血管危险因素导致的主要非癌症死亡原因。本研究旨在开发和验证机器学习（ML）模型，以预测美国人口水平上I-II期激素受体阳性乳腺癌老年妇女的全因、乳腺癌相关和cvd相关死亡率。为了解决与衰老相关的异质性，我们为两个年龄组（66-79岁和≥80岁）创建了单独的模型。材料和方法：使用2006-2019年SEER-Medicare数据库，我们确定了年龄≥66岁的诊断为I-II期乳腺癌的女性，这些女性代表了早期侵袭性疾病，她们在2007年至2009年期间开始了辅助内分泌治疗（AET）。将AET使用的第一个日期定义为索引日期。我们评估了在索引日期前一年存在的合并症，并随访患者长达10年或直到死亡。结果包括全因死亡率、乳腺癌相关死亡率和心血管疾病相关死亡率。我们使用基于决策树的算法开发了两个年龄组的生存预测模型。采用受试者工作特征曲线下平均面积（AUROC）评价模型性能，采用Shapley加性解释增强模型可解释性。结果：在10104名女性中，使用随机生存森林算法（RSF）的6个模型均达到平均AUROC bb0 0.7，表明具有较强的预测性能。对于全因死亡率，两个年龄组的关键预测因素包括年龄、疑似疾病筛查（未诊断的异常发现）和充血性心力衰竭。肿瘤大小、癌症分期和继发恶性肿瘤最能预测乳腺癌相关死亡率，而充血性心力衰竭、心脏瓣膜疾病和其他不明确的心脏疾病是心血管疾病相关死亡率的关键因素。讨论：我们使用基于决策树的算法开发了基于ml的跨结果和年龄组的生存模型，以预测老年1 - ii期乳腺癌妇女的死亡率。RSF表现出最好的效果，年龄、疑似疾病筛查和充血性心力衰竭一直是关键的预测因素。针对这些因素可能会提高心脏肿瘤的护理。

{"title":"Long-term survival prediction in older women with stage I-II breast cancer using decision tree-based machine learning","authors":"Hyuna Yoon , Yeijin Kim , Sola Han , Hae Sun Suh , Chanhyun Park","doi":"10.1016/j.jgo.2025.102828","DOIUrl":"10.1016/j.jgo.2025.102828","url":null,"abstract":"<div><h3>Introduction</h3><div>Predicting survival in older women with early breast cancer can guide personalized care and improve outcomes. Aging is an individualized process that influences tumor characteristics and survival, with cardiovascular disease (CVD) being the leading non-cancer cause of death due to cardiovascular risk factors. This study aimed to develop and validate machine learning (ML) models to predict all-cause, breast cancer-related, and CVD-related mortality in older women with stage I-II, hormone receptor-positive breast cancer at the U.S. population level. To address the heterogeneity associated with aging, we created separate models for two age groups (66–79 and ≥ 80 years).</div></div><div><h3>Materials and methods</h3><div>Using the 2006–2019 SEER–Medicare database, we identified women aged ≥66 years diagnosed with stage I–II breast cancer, representing early-stage invasive disease, who initiated adjuvant endocrine therapy (AET) between 2007 and 2009. The first date of AET use was defined as the index date. We assessed pre-existing comorbidities during the one year prior to the index date and followed patients for up to 10 years or until death. Outcomes included all-cause mortality, breast cancer-related mortality, and CVD-related mortality. We developed survival prediction models using the decision tree-based algorithms for the two age groups. Model performance was evaluated using the mean area under the receiver operating characteristic curve (AUROC), and model interpretability was enhanced using Shapley Additive Explanations.</div></div><div><h3>Results</h3><div>Among 10,104 women, all six models achieved a mean AUROC >0.7 using the random survival forest algorithm (RSF), indicating strong predictive performance. For all-cause mortality, key predictors in both age groups included age, screenings for suspected conditions (abnormal findings without diagnosis), and congestive heart failure. Tumor size, cancer stage, and secondary malignancies were most predictive of breast cancer-related mortality, while congestive heart failure, heart valve disorders, and other ill-defined heart diseases were critical for CVD-related mortality.</div></div><div><h3>Discussion</h3><div>We developed ML-based survival models across outcomes and age group using the decision tree-based algorithms to predict mortality in older women with stage I-II breast cancer. RSF demonstrated the best performance, with age, screenings for suspected conditions, and congestive heart failure consistently emerging as key predictors. Targeting these factors may enhance cardio-oncology care.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102828"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145774917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of an older adult-centred cancer program at an academic centre in Ontario, Canada: Initial steps and early successes 加拿大安大略省某学术中心以老年人为中心的癌症项目的发展：初步步骤和早期成功。

IF 2.7 3区医学 Q3 GERIATRICS & GERONTOLOGY

Journal of geriatric oncology

Pub Date : 2026-03-01 Epub Date: 2025-12-17 DOI: 10.1016/j.jgo.2025.102838

Taleen Haddad , Karen Misquitta , Shaila J. Merchant

引用次数: 0

Comorbidity cluster trajectories across the care continuum in older women with breast cancer initiating adjuvant endocrine therapy 开始辅助内分泌治疗的老年乳腺癌妇女的共病簇轨迹

IF 2.7 3区医学 Q3 GERIATRICS & GERONTOLOGY

Journal of geriatric oncology

Pub Date : 2026-03-01 Epub Date: 2026-01-19 DOI: 10.1016/j.jgo.2026.102852

Sola Han , Hyejoong M. Lee , Chanhyun Park

Introduction

With the growing population of older breast cancer survivors, understanding how chronic comorbidities evolve across treatment and toward the end-of-life (EOL) is increasingly important. We aimed to characterize temporal and EOL patterns of comorbidity clusters before and after adjuvant endocrine therapy (AET) among women aged 66–79 years and ≥ 80 years with breast cancer.

Materials and methods

We used the 2016–2019 SEER-Medicare data to identify women aged ≥66 years who initiated AET in 2017. Eligible patients had hormone receptor–positive, stage I–III breast cancer diagnosed within one year prior to AET initiation (index date). Comorbidities were defined using Clinical Classifications Software Refined (CCSR) codes. To identify comorbidity patterns, we applied agglomerative hierarchical clustering using Jaccard's dissimilarity index and Ward's minimum variance method to the top 50 CCSR categories across four periods: pre-index, post–year 1, post–year 2, and EOL.

Results

We identified 11,551 women, of whom 11,050 were alive at the end of follow-up and 501 died during follow-up. Among the patients who were alive, more than 50% had ≥2 chronic conditions across the observation windows. Cardiovascular diseases and their associated risk factors showed the largest increase over time. The most consistent and prevalent cluster across post–year 1, post–year 2, and EOL was “cardiovascular and pulmonary diseases,” including hypertension, coronary atherosclerosis, with additional respiratory and kidney-related conditions emerging near EOL.

Discussion

Comorbidity clustering was common and persisted across observation windows, with cardiovascular and related conditions prominent and expanding near EOL. These patterns highlight the need for integrated cardio-oncology and geriatric co-management to address the complex care needs of older women receiving AET.

随着老年乳腺癌幸存者人数的增加，了解慢性合并症如何在治疗过程中演变并走向生命末期（EOL）变得越来越重要。我们的目的是描述66-79岁和≥80岁的乳腺癌患者在辅助内分泌治疗（AET）前后合并症群的时间和EOL模式。材料和方法：我们使用2016-2019年SEER-Medicare数据来识别2017年开始AET的年龄≥66岁的女性。符合条件的患者在AET开始前一年内诊断为激素受体阳性的I-III期乳腺癌（索引日期）。使用临床分类软件改进（CCSR）代码定义合并症。为了确定共病模式，我们使用Jaccard的不相似指数和Ward的最小方差法对四个时期的前50个CCSR类别进行了聚集层次聚类：指数前、1年后、2年后和EOL。结果：我们确定了11,551名女性，其中11,050名在随访结束时存活，501名在随访期间死亡。在存活的患者中，超过50%的患者在观察期内患有≥2种慢性疾病。随着时间的推移，心血管疾病及其相关风险因素的增加幅度最大。在1年后、2年后和EOL中，最一致和最普遍的一类是“心血管和肺部疾病”，包括高血压、冠状动脉粥样硬化，在EOL附近出现额外的呼吸和肾脏相关疾病。讨论：合并症聚类是常见的，并且在整个观察窗口中持续存在，心血管和相关疾病在EOL附近突出并扩大。这些模式强调需要综合的心脏肿瘤学和老年联合管理，以解决接受AET的老年妇女的复杂护理需求。

{"title":"Comorbidity cluster trajectories across the care continuum in older women with breast cancer initiating adjuvant endocrine therapy","authors":"Sola Han , Hyejoong M. Lee , Chanhyun Park","doi":"10.1016/j.jgo.2026.102852","DOIUrl":"10.1016/j.jgo.2026.102852","url":null,"abstract":"<div><h3>Introduction</h3><div>With the growing population of older breast cancer survivors, understanding how chronic comorbidities evolve across treatment and toward the end-of-life (EOL) is increasingly important. We aimed to characterize temporal and EOL patterns of comorbidity clusters before and after adjuvant endocrine therapy (AET) among women aged 66–79 years and ≥ 80 years with breast cancer.</div></div><div><h3>Materials and methods</h3><div>We used the 2016–2019 SEER-Medicare data to identify women aged ≥66 years who initiated AET in 2017. Eligible patients had hormone receptor–positive, stage I–III breast cancer diagnosed within one year prior to AET initiation (index date). Comorbidities were defined using Clinical Classifications Software Refined (CCSR) codes. To identify comorbidity patterns, we applied agglomerative hierarchical clustering using Jaccard's dissimilarity index and Ward's minimum variance method to the top 50 CCSR categories across four periods: pre-index, post–year 1, post–year 2, and EOL.</div></div><div><h3>Results</h3><div>We identified 11,551 women, of whom 11,050 were alive at the end of follow-up and 501 died during follow-up. Among the patients who were alive, more than 50% had ≥2 chronic conditions across the observation windows. Cardiovascular diseases and their associated risk factors showed the largest increase over time. The most consistent and prevalent cluster across post–year 1, post–year 2, and EOL was “cardiovascular and pulmonary diseases,” including hypertension, coronary atherosclerosis, with additional respiratory and kidney-related conditions emerging near EOL.</div></div><div><h3>Discussion</h3><div>Comorbidity clustering was common and persisted across observation windows, with cardiovascular and related conditions prominent and expanding near EOL. These patterns highlight the need for integrated cardio-oncology and geriatric co-management to address the complex care needs of older women receiving AET.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102852"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146010898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oncogeriatric assessment: Expert consensus recommendations in Chile 老年肿瘤评估：智利专家共识建议。

IF 2.7 3区医学 Q3 GERIATRICS & GERONTOLOGY

Journal of geriatric oncology

Pub Date : 2026-03-01 Epub Date: 2026-01-19 DOI: 10.1016/j.jgo.2026.102847

Rocío Quilodrán Loyola , Gabriel Martínez Fuentes , Isidora Jiménez Álvarez , Evangelina Röling , Gonzalo Navarrete Hernández

引用次数: 0

One voice for radiotherapy: Addressing inequities in radiotherapy utilization for older adults 放疗的一个声音：解决老年人放疗利用中的不公平现象。

IF 2.7 3区医学 Q3 GERIATRICS & GERONTOLOGY

Journal of geriatric oncology

Pub Date : 2026-03-01 Epub Date: 2026-02-04 DOI: 10.1016/j.jgo.2026.102899

Penny Mackenzie , Geoff Delaney , Lucinda Morris , Anita O'Donovan

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of geriatric oncology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀